Emerging New Therapeutic Modalities

Sunday, November 10, 2024

1:45 PM – 3:00 PM MST

Location: Sonoran Sky Ballroom 4

Moderator(s)

Joy Hsu, PhD

Director, Clinical Pharmacology and Pharmacometrics
Genentech
South San Francisco, California, United States

Speaker(s)

Samira Khalili (she/her/hers)

Director of Pharmacokinetics and Clinical Pharmacology
Ionis
Menlo Park, California, United States
DY

Donghua Yin, PhD

Vice President, Head of Clinical Pharmacology, Pfizer Oncology Division
Pfizer, California, United States
Eric Masson, PharmD

SVP, Early Clinical Development
Arvinas
Essex, Connecticut, United States

Disclosure(s):

Joy C. Hsu, PhD: Roche: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Samira Khalili: Ionis Pharmaceuticals: Employment (Ongoing); Takeda: Employment (Terminated, August 5, 2023)

Donghua Yin, PhD: Pfizer Inc: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Eric Masson, PharmD: Arvinas: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Presentations:

1:45 PM – 2:10 PM MST

Applications of A Platform PBPK Model of Antisense Oligonucleotides Towards Candidate Selection, Tox Study Design and Human Dose Projection
Speaker: Samira Khalili (she/her/hers) – Ionis
2:10 PM – 2:35 PM MST

Model-Informed Drug Development Applications to Oncology Bispecifics and Antibody-Drug Conjugates
Speaker: Donghua Yin, PhD – Pfizer
2:35 PM – 3:00 PM MST

Unique Model Informed Drug Development Opportunities with PROTAC Protein Degrader
Speaker: Eric Masson, PharmD – Arvinas